The DOI matches its Crossref record; 23 of the 23 references it cites were found in a registry or an index.
Membrane-Proximal Epitope Facilitates Efficient T Cell Synapse Formation by Anti-FcRH5/CD3 and Is a Requirement for Myeloma Cell Killing
Open accessAbstract
The anti-FcRH5/CD3 T cell-dependent bispecific antibody (TDB) targets the B cell lineage marker FcRH5 expressed in multiple myeloma (MM) tumor cells. We demonstrate that TDBs trigger T cell receptor activation by inducing target clustering and exclusion of CD45 phosphatase from the synapse. The dimensions of the target molecule play a key role in the efficiency of the synapse formation. The anti-FcRH5/CD3 TDB kills human plasma cells and patient-derived myeloma cells at picomolar concentrations and results in complete depletion of B cells and bone marrow plasma cells in cynomolgus monkeys. These data demonstrate the potential for the anti-FcRH5/CD3 TDB, alone or in combination with inhibition of PD-1/PD-L1 signaling, in the treatment of MM and other B cell malignancies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Genotype-Tissue Expression (GTEx) pilot analysis: Multitissue gene regulation in humans
The GTEx Consortium, Ardlie, K. G., Deluca, D. S., Segrè, A. V., Sullivan, T. J., Young, T. R., Gelfand, E. T., Trowbridge, C. A., Maller, J. B., Tukiainen, T., et al. (2015) · Science · doi:10.1126/science.1262110 · Cited by 5,062
Tumor Regression in Cancer Patients by Very Low Doses of a T Cell–Engaging Antibody
Bargou, R., Leo, E., Zugmaier, G., Klinger, M., Goebeler, M., Knop, S., Noppeney, R., Viardot, A., Hess, G., Schuler, M., et al. (2008) · Science · doi:10.1126/science.1158545 · Cited by 1,078
Rapoport, A. P., Stadtmauer, E. A., Binder-Scholl, G. K., Goloubeva, O., Vogl, D. T., Lacey, S. F., Badros, A. Z., Garfall, A., Weiss, B., Finklestein, J., et al. (2015) · Nature Medicine · doi:10.1038/nm.3910 · Cited by 856
Chimeric Antigen Receptor T Cells against CD19 for Multiple Myeloma
Garfall, A. L., Maus, M. V., Hwang, W.-T., Lacey, S. F., Mahnke, Y. D., Melenhorst, J. J., Zheng, Z., Vogl, D. T., Cohen, A. D., Weiss, B. M., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504542 · Cited by 624
Chauhan, D., Tian, Z., Nicholson, B., Kumar, K. G. S., Zhou, B., Carrasco, R., McDermott, J. L., Leach, C. A., Fulcinniti, M., Kodrasov, M. P., et al. (2012) · Cancer Cell · doi:10.1016/j.ccr.2012.08.007 · Cited by 589
The kinetic-segregation model: TCR triggering and beyond
Davis, S. J., & van der Merwe, P. A. (2006) · Nature Immunology · doi:10.1038/ni1369 · Cited by 561
Offner, S., Hofmeister, R., Romaniuk, A., Kufer, P., & Baeuerle, P. A. (2006) · Molecular Immunology · doi:10.1016/j.molimm.2005.03.007 · Cited by 365
Bacac, M., Fauti, T., Sam, J., Colombetti, S., Weinzierl, T., Ouaret, D., Bodmer, W., Lehmann, S., Hofer, T., Hosse, R. J., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-1696 · Cited by 345
Boyd, K. D., Ross, F. M., Chiecchio, L., Dagrada, G. P., Konn, Z. J., Tapper, W. J., Walker, B. A., Wardell, C. P., Gregory, W. M., Szubert, A. J., et al. (2012) · Leukemia · doi:10.1038/leu.2011.204 · Cited by 340
Biophysical mechanism of T-cell receptor triggering in a reconstituted system
James, J. R., & Vale, R. D. (2012) · Nature · doi:10.1038/nature11220 · Cited by 323
Self-citation
Cited by
Bispecific antibodies: a mechanistic review of the pipeline
Labrijn, A. F., Janmaat, M. L., Reichert, J. M., & Parren, P. W. H. I. (2019) · Nature Reviews Drug Discovery · doi:10.1038/s41573-019-0028-1 · Cited by 1,303
The present and future of bispecific antibodies for cancer therapy
Klein, C., Brinkmann, U., Reichert, J. M., & Kontermann, R. E. (2024) · Nature Reviews Drug Discovery · doi:10.1038/s41573-024-00896-6 · Cited by 490
A review of bispecific antibodies and antibody constructs in oncology and clinical challenges
Suurs, F. V., Lub-de Hooge, M. N., de Vries, E. G. E., & de Groot, D. J. A. (2019) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2019.04.006 · Cited by 292
T-cell-engaging bispecific antibodies in cancer
van de Donk, N. W. C. J., & Zweegman, S. (2023) · The Lancet · doi:10.1016/s0140-6736(23)00521-4 · Cited by 267
Engelberts, P. J., Hiemstra, I. H., de Jong, B., Schuurhuis, D. H., Meesters, J., Beltran Hernandez, I., Oostindie, S. C., Neijssen, J., van den Brink, E. N., Horbach, G. J., et al. (2020) · EBioMedicine · doi:10.1016/j.ebiom.2019.102625 · Cited by 172
Pillarisetti, K., Edavettal, S., Mendonça, M., Li, Y., Tornetta, M., Babich, A., Majewski, N., Husovsky, M., Reeves, D., Walsh, E., et al. (2020) · Blood · doi:10.1182/blood.2019003342 · Cited by 174
Mandikian, D., Takahashi, N., Lo, A. A., Li, J., Eastham-Anderson, J., Slaga, D., Ho, J., Hristopoulos, M., Clark, R., Totpal, K., et al. (2018) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-17-0657 · Cited by 155
Self-citationGPRC5D as a novel target for the treatment of multiple myeloma: a narrative review
Rodriguez-Otero, P., van de Donk, N. W. C. J., Pillarisetti, K., Cornax, I., Vishwamitra, D., Gray, K., Hilder, B., Tolbert, J., Renaud, T., Masterson, T., et al. (2024) · Blood Cancer Journal · doi:10.1038/s41408-023-00966-9 · Cited by 113
Anti-GPRC5D/CD3 Bispecific T-Cell–Redirecting Antibody for the Treatment of Multiple Myeloma
Kodama, T., Kochi, Y., Nakai, W., Mizuno, H., Baba, T., Habu, K., Sawada, N., Tsunoda, H., Shima, T., Miyawaki, K., et al. (2019) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-18-1216 · Cited by 80
“GPRC5D mRNA expression in Genotype-Tissue Expression (GTEx) sample set containing 8,555 samples from53different human tissueswas analyzed by the GTEx consortium (19, 20).”
MethodJiang, X., Chen, X., Carpenter, T. J., Wang, J., Zhou, R., Davis, H. M., Heald, D. L., & Wang, W. (2018) · mAbs · doi:10.1080/19420862.2018.1480299 · Cited by 60
Panowski, S. H., Kuo, T. C., Zhang, Y., Chen, A., Geng, T., Aschenbrenner, L., Kamperschroer, C., Pascua, E., Chen, W., Delaria, K., et al. (2019) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-19-0007 · Cited by 48
Computational stabilization of T cell receptors allows pairing with antibodies to form bispecifics
Froning, K., Maguire, J., Sereno, A., Huang, F., Chang, S., Weichert, K., Frommelt, A. J., Dong, J., Wu, X., Austin, H., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-16231-7 · Cited by 37
Solution structure and synaptic analyses reveal determinants of bispecific T cell engager potency
Leithner, A., Staufer, O., Mitra, T., Liberta, F., Valvo, S., Kutuzov, M., Dada, H., Spaeth, J., Zhou, W., Schiele, F., et al. (2025) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2425781122 · Cited by 22
Metadata
- Authors
- Li, J., Stagg, N. J., Johnston, J., Harris, M. J., Menzies, S. A., DiCara, D., Clark, V., Hristopoulos, M., Cook, R., Slaga, D., Nakamura, R., McCarty, L., Sukumaran, S., Luis, E., Ye, Z., Wu, T. D., Sumiyoshi, T., Danilenko, D., Lee, G. Y., Totpal, K., Ellerman, D., Hötzel, I., James, J. R., & Junttila, T. T.
- Venue
- Cancer Cell
- Publisher
- Elsevier BV
- Published
- 2017-03
- Volume
- 31
- Issue
- 3
- Pages
- 383-395
- ISSN
- 1535-6108 (ISSN-L)
- OpenAlex
- W2592173429
- Cited by
- 296
- References
- 23
- FWCI
- 15.53
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.